Medicine and Dentistry
Adjuvant Chemotherapy
8%
Adjuvant Therapy
10%
Arm
6%
Aromatase Inhibitor
5%
Biological Marker
8%
Breast Cancer
100%
Cancer Therapy
7%
Clinical Oncology
12%
Clinical Trial
12%
Clinician
6%
Disease
11%
Disease Free Survival
7%
Epidermal Growth Factor Receptor 2
17%
Estrogen Receptor
8%
Gamma Urogastrone
18%
Hazard Ratio
6%
Hormone Receptor
9%
Hormone Therapy
10%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
13%
Lapatinib
6%
Malignant Neoplasm
24%
Metastatic Breast Cancer
10%
Neoplasm
13%
Oncology
12%
Overall Survival
8%
Paclitaxel
7%
Pathologist
8%
Progesterone Receptor
5%
Recurrent Disease
13%
Survivorship in Cancer Care
8%
Symptom
5%
Systematic Review
5%
Targeted Therapy
6%
Trastuzumab
20%
Triple Negative Breast Cancer
10%
Pharmacology, Toxicology and Pharmaceutical Science
Anthracycline
5%
Breast Cancer
60%
Capecitabine
5%
Chemotherapy
21%
Clinical Trial
9%
Cyclophosphamide
5%
Disease
11%
Disease Free Survival
8%
Docetaxel
5%
Doxorubicin
6%
Endocrine Therapy
5%
Epidermal Growth Factor Receptor 2
11%
Gamma Urogastrone
13%
Hormone Receptor
9%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
13%
Lapatinib
7%
Malignant Neoplasm
14%
Metastatic Breast Cancer
11%
Neoplasm
13%
Overall Survival
9%
Paclitaxel
13%
Phase II Trials
5%
Recurrent Disease
10%
Taxane
6%
Trastuzumab
19%
Triple Negative Breast Cancer
7%
Keyphrases
Adjuvant Therapy
5%
American Society of Clinical Oncology
6%
Breast Cancer
30%
Breast Cancer Treatment
5%
Chemotherapy
8%
Clinical Practice Guidelines
5%
Clinical Trials
5%
College of American Pathologists
6%
Disease-free Survival
7%
Early Breast Cancer
14%
Endocrine Therapy
8%
Estrogen Receptor
5%
Hazard Ratio
8%
Human Epidermal Growth Factor Receptor 2 (HER2)
12%
Invasive Breast Cancer
6%
Lapatinib
5%
Metastatic Breast Cancer
12%
Overall Survival
5%
Paclitaxel
6%
Pathological Complete Response
6%
Phase II Study
5%
Randomized Clinical Trial
5%
Trastuzumab
12%
Triple-negative Breast Cancer
7%
Tumor
6%